Emyria (EMD) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock EMD Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Top 10 at 11: ASX slides 0.2pc as geopolitical threat to crude supply escalatesJune 17 at 10:16 PM | msn.comEmyria Partners with Medibank to Fund PTSD Program, Expanding National Mental Health CareJune 17 at 9:58 PM | tipranks.comEmyria Limited Requests Trading Halt Ahead of Major AnnouncementJune 15 at 10:54 PM | tipranks.comEmyria Reports Promising Six-Month PTSD Treatment OutcomesMay 27, 2025 | tipranks.comEmyria opens second Empax centre in Perth to meet mental health demandApril 14, 2025 | msn.comEmyria Expands Mental Health Services with New Empax CentreApril 13, 2025 | tipranks.comEmyria Limited Updates Director’s Interest with Strategic Share AcquisitionMarch 31, 2025 | tipranks.comEmyria Limited Issues New Shares for Immediate TradingMarch 31, 2025 | tipranks.comFavourable Signals For Emyria: Numerous Insiders Acquired StockMarch 5, 2025 | finance.yahoo.comEmyria Issues New Shares to Boost Market LiquidityMarch 4, 2025 | tipranks.comEmyria Limited Announces General Meeting to Ratify and Approve Share IssuancesFebruary 13, 2025 | tipranks.comEmyria Limited Announces General Meeting for ShareholdersFebruary 13, 2025 | tipranks.comHealth Check: Good golly Miss Molly! Emyria says Ecstasy works for PTSD, months after treatmentFebruary 3, 2025 | msn.comEmyria to plug $2.5M into depression treatment program at Empax CentreNovember 26, 2024 | msn.comEmyria Limited Plans Major Securities IssuanceNovember 26, 2024 | tipranks.comHealth Check: Actinogen powers ahead with key Alzheimer’s disease trialNovember 14, 2024 | msn.comEmyria Limited Announces Successful AGM ResolutionsNovember 11, 2024 | tipranks.comEmyria, UWA seek commercialisation of compounds to treat PTSD and Parkinson'sOctober 31, 2024 | msn.comEmyria Ltd Announces Key Growth and Innovation MilestonesOctober 30, 2024 | markets.businessinsider.comEmyria Gains Key Endorsement for Psychedelic TherapiesOctober 28, 2024 | msn.comEmyria Ltd Ordinary SharesOctober 22, 2024 | morningstar.comInsider Spends AU$300k Buying More Shares In EmyriaSeptember 25, 2024 | finance.yahoo.comAlive and Kicking: Lumos Diagnostics attracts ‘Twiggy’ Forrest as cornerstone holder in $10m raiseSeptember 3, 2024 | msn.comEmyria Full Year 2024 Earnings: AU$0.032 loss per share (vs AU$0.018 loss in FY 2023)September 1, 2024 | finance.yahoo.comUS March deficit shrinks as outlays fall, tax receipts riseApril 11, 2024 | finance.yahoo.comEmyria opens Empax Centre to target care gaps in resistant PTSDApril 10, 2024 | finance.yahoo.comEmyria Slides As Insider Purchases Lose Another AU$300kJanuary 29, 2024 | finance.yahoo.comEmyria kicks off year with $2.5 million R&D incentive on the heels of Authorised Prescriber statusJanuary 14, 2024 | au.investing.comSEC gives Bitcoin ETFs the long-awaited green lightJanuary 10, 2024 | proactiveinvestors.com.auEmyria sharpens focus on delivering MDMA treatments for PTSD patientsJanuary 10, 2024 | proactiveinvestors.com.auClosing Bell: The ASX got slow-boiled like a frog in a pot to close at -0.69pc downJanuary 10, 2024 | msn.comASX Health Stocks: Emyria surges 19pc after granting of ‘Authorised Prescriber’ status by TGAJanuary 9, 2024 | msn.comEmyria welcomes top healthcare leader as chairmanNovember 21, 2023 | proactiveinvestors.com.auEmyria restructures board amid cost efficiency commitmentNovember 12, 2023 | proactiveinvestors.com.auIt's Unlikely That Shareholders Will Increase Emyria Limited's (ASX:EMD) Compensation By Much This YearNovember 9, 2023 | finance.yahoo.comEmyria secures ethics endorsement for MDMA Authorised Prescriber application, clearing way for TGA decisionOctober 30, 2023 | proactiveinvestors.com.auEmyria hails strong growth in clinical billingsOctober 26, 2023 | finance.yahoo.comEmyria given green light to import MDMA for therapeutic trials in AustraliaOctober 21, 2023 | proactiveinvestors.com.auEmyria completes entitlement offer, raises $1.18m ahead of MDMA-assisted therapy trialOctober 5, 2023 | au.investing.comEmyria set to begin MDMA study after securing local supplySeptember 26, 2023 | finance.yahoo.comEmyria provides unique combination of drug development and therapy deliverySeptember 7, 2023 | finance.yahoo.comClosing Bell: Liontown’s kitty is sitting pretty; Benchmark makes most of Monday ahead of RBA meetSeptember 4, 2023 | msn.comEmyria raises $2 million in placement; launches $3.1 million entitlement offerSeptember 4, 2023 | proactiveinvestors.com.auTop 10 at 11: Emyria soars on funding news, and loads of tasty stuff unearthed in Canada.September 3, 2023 | msn.comEmyria Full Year 2023 Earnings: AU$0.018 loss per share (vs AU$0.027 loss in FY 2022)September 1, 2023 | finance.yahoo.comEmyria advances development and commercialisation of unique drug productsAugust 1, 2023 | finance.yahoo.comEmyria recruits first patient for MDMA-assisted therapy trialJuly 11, 2023 | proactiveinvestors.com.auEmyria expands mental health care capabilities with Pax Centre acquisitionJuly 3, 2023 | proactiveinvestors.com.auEmyria hails ethics approval for MDMA-assisted clinical trialJune 8, 2023 | proactiveinvestors.com.auEmyria gains ethics approval for landmark MDMA-assisted PTSD therapy trialJune 7, 2023 | proactiveinvestors.com.au Get Emyria News Delivered to You Automatically Sign up to receive the latest news and ratings for EMD and its competitors with MarketBeat's FREE daily newsletter. Email Address EMD Media Mentions By Week EMD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EMD News Sentiment▼-0.420.56▲Average Medical News Sentiment EMD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EMD Articles This Week▼30▲EMD Articles Average Week Get Emyria News Delivered to You Automatically Sign up to receive the latest news and ratings for EMD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Forian News Today Kooth News Today Renalytix News Today Cambridge Cognition News Today Induction Healthcare Group News Today Feedback News Today CardioComm Solutions News Today IQ-AI News Today Aclarion News Today BrightSpring Health Services News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (ASX:EMD) was last updated on 6/18/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon’s End Game Is Going Live -- And It Could Make You a FortuneThe media and the so-called experts have laughed at Elon Musk his entire career. CBS called PayPal “one of ...The Oxford Club | SponsoredSorry about the swear wordWhat a huge few months for Bitcoin. First, Bitcoin hit $100,000… Then, Donald Trump pledged to create an...Manward Press | SponsoredThe Dollar Reset Nobody’s Talking AboutCould this man take down the financial system? In March, the Senate granted sweeping powers to a Harvard ec...Stansberry Research | SponsoredBREAKING: Trump vs. Elon Feud Threatens Your Retirement – Protect Yourself NOW"This isn't just a war of words. This is a financial time bomb. The escalating battle between Donald Trump a...American Alternative | SponsoredThis is not your typical AI storyThe market’s biggest AI winners? You’ve never heard of them. Everyone’s obsessed with AI stocks like Nvidia...Market Traders Daily | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Emyria Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Emyria With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
